Last reviewed 2026-04-20 · How we verify

Bystolic (nebivolol)

At a glance

Approved indications

• Hypertensive disorder

Common side effects

• Headache
• Dizziness
• Fatigue
• Nausea
• Gastrointestinal Disorders
• Dyspnea
• Insomnia
• Rash
• Respiratory Disorders
• Asthenia
• Abdominal Pain
• Paraesthesia

Serious adverse events

• Bradycardia
• Cardiac Disorders

Key clinical trials

• An Open Label, 2-part, One-sequence, 3-period Study to Evaluate Drug-drug Interactions Between "DWN12088" and "Nebivolol" or "Paroxetine" in Healthy Male Volunteers (Phase 1)
• Effects of Dapagliflozin on Hypotensive Patients With Depressed Left Ventricular Ejection Fraction After Sacubitril/Valsartan Therapy (Phase 4)
• Evaluation of the Cardioprotective Effect of Nebivolol on Trastuzumab-Induced Cardiotoxicity in Breast Cancer Patients (Phase 2)
• Collaborative Systematic Overview of Randomised Controlled Trials of Beta-Blockers in the Treatment of Heart Failure (N/A)
• Nebivolol Vs. Metoprolol: Comparative Effects on Fatigue and Quality of Life (Phase 4)
• Comparative Effects of Nebivolol Versus Metoprolol on 24-hour Blood Pressures and Basal Metabolic Rate: An Open-Label Study (NA)
• Comparative Study of the Effects of Telmisartan and Nebivolol on 24-h Ambulatory Blood Pressure and Arterial Stiffness in Patients With Arterial Hypertension (Phase 4)
• A Double-blind, Placebo-controlled, Randomized Study Examining the Effects of Nebivolol Compared to Atenolol on Endothelial Function and Cardiovascular Risk in Patients With Early Vascular Disease (Phase 2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Bystolic CI brief — competitive landscape report
• Bystolic updates RSS · CI watch RSS
• Allergan portfolio CI